Clinical Trial Update: Evaluation of Absorption, Metabolism, and Excretion and Estimation of the Absolute Bioavailability of K-312 [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetic study assessing absorption, metabolism, excretion, and absolute bioavailability of the investigational drug K-312 in subjects with dys…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• K-312

Snippet

Sponsor: Kowa Research Institute, Inc. | Conditions: Dyslipidemia | Phase 1 | Status: COMPLETED